Tommy Eriksson
Research Subjects
Tommy Eriksson has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Peter Höglund
Competence Centre for Clinical Research, Skåne University Hospital, Lund, Sweden
4 shared publications Sven Björkman
Hospital Pharmacy, Malmö University Hospital, Malmö, Sweden
2 shared publicationsA. Waage
Department of Haematology, University Hospital , 7006 Trondheim
1 shared publicationAsa Bondesson
1 shared publicationB. R. Don
Department of Haematology, University Hospital , 7006 Trondheim
1 shared publicationBodil Roth
Hospital Pharmacy, MUH
1 shared publication
Latest Publications
- 1 November 2005
- Vol. 102 (40) , 2874-5
[Medication records reduce medication errors when transferring and discharging hospitalized patients].
- 1 November 2005
- Vol. 102 (40) , 2874-5
[Medication records reduce medication errors when transferring and discharging hospitalized patients].
- 1 December 2003
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 55 (12) , 1701-1706
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis
There is a renewed interest in thalidomide for use in malignancies and systemic inflammatory diseases. Reduced renal function is not uncommon among patients with these disease states but the pharmacokinetics has not been fully investigated. The aim of this study was to investigate the pharmacokinetics of thalidomide in haemodialysis patients while on and off dialysis and in myeloma patients with varying degrees of renal function. Two studies were performed. To establish the pharmacokinetics of thalidomide in patients with mild to moderate renal failure, blood samples were taken over 12 weeks from 40 patients with multiple myeloma. A second study was performed in six patients with end‐stage renal disease both on a non‐dialysis day and before and during a haemodialysis session. Thalidomide concentration was determined by HPLC. A one‐compartment open model with first‐order absorption and elimination was used to fit total thalidomide concentration to population pharmacokinetics and statistical models using the NONMEM program. Clearance and volumes were slightly below 10 L h−1 and 1 L kg−1, respectively, in both patient groups. The inter‐ and intra‐patient variability was low. Clearance was doubled during dialysis. There was no correlation between thalidomide clearance and renal function. In conclusion, the pharmacokinetics of thalidomide in patients with renal failure are very similar to values reported by others for patients with normal renal function. Although clearance during dialysis is doubled, thalidomide dose need not be changed for patients with decreased kidney function. There is also no need for a supplementary dose due to haemodialysis.
- 1 December 2003
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 55 (12) , 1701-1706
Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis
There is a renewed interest in thalidomide for use in malignancies and systemic inflammatory diseases. Reduced renal function is not uncommon among patients with these disease states but the pharmacokinetics has not been fully investigated. The aim of this study was to investigate the pharmacokinetics of thalidomide in haemodialysis patients while on and off dialysis and in myeloma patients with varying degrees of renal function. Two studies were performed. To establish the pharmacokinetics of thalidomide in patients with mild to moderate renal failure, blood samples were taken over 12 weeks from 40 patients with multiple myeloma. A second study was performed in six patients with end‐stage renal disease both on a non‐dialysis day and before and during a haemodialysis session. Thalidomide concentration was determined by HPLC. A one‐compartment open model with first‐order absorption and elimination was used to fit total thalidomide concentration to population pharmacokinetics and statistical models using the NONMEM program. Clearance and volumes were slightly below 10 L h−1 and 1 L kg−1, respectively, in both patient groups. The inter‐ and intra‐patient variability was low. Clearance was doubled during dialysis. There was no correlation between thalidomide clearance and renal function. In conclusion, the pharmacokinetics of thalidomide in patients with renal failure are very similar to values reported by others for patients with normal renal function. Although clearance during dialysis is doubled, thalidomide dose need not be changed for patients with decreased kidney function. There is also no need for a supplementary dose due to haemodialysis.
- 13 July 2001
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 57 (5) , 365-376
Clinical pharmacology of thalidomide
Background: Thalidomide has a chiral centre, and the racemate of (R)- and (S)-thalidomide was introduced as a sedative drug in the late 1950s. In 1961, it was withdrawn due to teratogenicity and neuropathy. There is now a growing clinical interest in thalidomide due to its unique anti-inflammatory and immunomodulatory effects. Objective: To critically review pharmacokinetic studies and briefly review pharmacodynamic effects and studies of thalidomide in consideration of its chemical and stereochemical properties and metabolism. Methods: Literature search and computer simulations of pharmacokinetics. Results: Rational use of thalidomide is problematic due to lack of basic knowledge of its mechanism of action, effects of the separate enantiomers and metabolites and dose- and concentration-effect relationships. Due to its inhibition of tumour necrosis factor-α and angiogenesis, racemic thalidomide has been tested with good effect in a variety of skin and mucous membrane disorders, Crohn's disease, graft-versus-host disease, complications to human immunodeficiency virus and, recently, in multiple myeloma. Adverse reactions are often related to the sedative effects. Irreversible toxic peripheral neuropathy and foetal malformations are serious complications that can be prevented. The results of several published pharmacokinetic studies can be questioned due to poor methodology and the use of non-stereospecific assays. The enantiomers of thalidomide undergo spontaneous hydrolysis and fast chiral interconversion at physiological pH. The oral bioavailability of thalidomide has not been unequivocally determined, but available data suggest that it is high. Absorption is slow, with a time to maximum plasma concentration of at least 2 h, and may also be dose-dependent; however, that of the separate enantiomers may be faster due to higher aqueous solubility. Estimation of the volume of distribution is complicated by probable hydrolysis and chiral inversion also in peripheral compartments. A value of around 1 l/kg is however plausible. Plasma protein binding is low with little difference between the enantiomers. Elimination of thalidomide is mainly by pH-dependent spontaneous hydrolysis in all body fluids with an apparent mean clearance of 10 l/h for the (R)- and 21 l/h for the (S)-enantiomer in adult subjects. Blood concentrations of the (R)-enantiomer are consequently higher than those of the (S)-enantiomer at pseudoequilibrium. The mean elimination half-life of both enantiomers is 5 h. One hydroxylated metabolite has been found in low concentrations in the blood. Since both enzymatic metabolism and renal excretion play minor roles in the elimination of thalidomide, the risk of drug interactions seems to be low. Conclusions: The interest in and use of thalidomide is increasing due to its potential as an immunomodulating and antiangiogenic agent. The inter-individual variability in distribution and elimination is low. Apart from this, its use is complicated by the lack of knowledge of dose– or concentration–effect relationships, possible dose-dependent oral absorption and of course by its well-known serious adverse effects.
- 13 July 2001
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 57 (5) , 365-376
Clinical pharmacology of thalidomide
Background: Thalidomide has a chiral centre, and the racemate of (R)- and (S)-thalidomide was introduced as a sedative drug in the late 1950s. In 1961, it was withdrawn due to teratogenicity and neuropathy. There is now a growing clinical interest in thalidomide due to its unique anti-inflammatory and immunomodulatory effects. Objective: To critically review pharmacokinetic studies and briefly review pharmacodynamic effects and studies of thalidomide in consideration of its chemical and stereochemical properties and metabolism. Methods: Literature search and computer simulations of pharmacokinetics. Results: Rational use of thalidomide is problematic due to lack of basic knowledge of its mechanism of action, effects of the separate enantiomers and metabolites and dose- and concentration-effect relationships. Due to its inhibition of tumour necrosis factor-α and angiogenesis, racemic thalidomide has been tested with good effect in a variety of skin and mucous membrane disorders, Crohn's disease, graft-versus-host disease, complications to human immunodeficiency virus and, recently, in multiple myeloma. Adverse reactions are often related to the sedative effects. Irreversible toxic peripheral neuropathy and foetal malformations are serious complications that can be prevented. The results of several published pharmacokinetic studies can be questioned due to poor methodology and the use of non-stereospecific assays. The enantiomers of thalidomide undergo spontaneous hydrolysis and fast chiral interconversion at physiological pH. The oral bioavailability of thalidomide has not been unequivocally determined, but available data suggest that it is high. Absorption is slow, with a time to maximum plasma concentration of at least 2 h, and may also be dose-dependent; however, that of the separate enantiomers may be faster due to higher aqueous solubility. Estimation of the volume of distribution is complicated by probable hydrolysis and chiral inversion also in peripheral compartments. A value of around 1 l/kg is however plausible. Plasma protein binding is low with little difference between the enantiomers. Elimination of thalidomide is mainly by pH-dependent spontaneous hydrolysis in all body fluids with an apparent mean clearance of 10 l/h for the (R)- and 21 l/h for the (S)-enantiomer in adult subjects. Blood concentrations of the (R)-enantiomer are consequently higher than those of the (S)-enantiomer at pseudoequilibrium. The mean elimination half-life of both enantiomers is 5 h. One hydroxylated metabolite has been found in low concentrations in the blood. Since both enzymatic metabolism and renal excretion play minor roles in the elimination of thalidomide, the risk of drug interactions seems to be low. Conclusions: The interest in and use of thalidomide is increasing due to its potential as an immunomodulating and antiangiogenic agent. The inter-individual variability in distribution and elimination is low. Apart from this, its use is complicated by the lack of knowledge of dose– or concentration–effect relationships, possible dose-dependent oral absorption and of course by its well-known serious adverse effects.
- 1 September 2000
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 57 (17) , 1607-1610
Low bioavailability of rectally administered thalidomide
Tommy Eriksson, Ph.D., Ronnie Wallin, M.Pharm.SCI., Peter HÖglund, M.D., Ph.D., Bodil Roth, Zhongquan Qi, M.D., Ph.D., Öyvind Östraat, M.D., Ph.D., Sven BjÖrkma
- 1 September 2000
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 57 (17) , 1607-1610
Low bioavailability of rectally administered thalidomide
Tommy Eriksson, Ph.D., Ronnie Wallin, M.Pharm.SCI., Peter HÖglund, M.D., Ph.D., Bodil Roth, Zhongquan Qi, M.D., Ph.D., Öyvind Östraat, M.D., Ph.D., Sven BjÖrkma